<DOC>
	<DOC>NCT01303978</DOC>
	<brief_summary>Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin</brief_summary>
	<brief_title>Phase II Proof-of-concept Study of APD421</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>1. Male or female patients ≥ 18 years of age 2. Ability and willingness to give written informed consent 3. Patients scheduled to receive, on day 1 of their chemotherapy, a first cisplatin chemotherapy infusion at a dose of 50 mg/m2 or greater 4. Karnofsky performance score ≥ 60% 5. Adequate cardiac, hepatic and renal function QTc interval &lt; 500 ms Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt; 5 x upper limit normal (ULN) Bilirubin &lt; 3 x ULN Creatinine &lt; 2 x ULN 6. Adequate haematological function Haemoglobin ≥ 9 g/dL White blood count ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L 7. For females of childbearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a doublebarrier method of contraception such as either an intrauterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards. 1. Patients scheduled to receive, prior to or in the 24 hours after cisplatin, any chemotherapeutic agent with a high or moderate emetic risk, see Appendix 4. 2. Patients scheduled to receive paclitaxel or docetaxel 3. Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin administration 4. Patients receiving APD421 for any indication within the last 2 weeks 5. Patients who are allergic to APD421 or any of the excipients of APD421 6. Patients with a preexisting vestibular disorder 7. Patients being treated with regular antiemetic therapy including corticosteroids 8. Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry 9. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin 10. Patients being treated with xxx 11. Patients receiving benzodiazepines, unless on a stable dose for at least one month prior to the expected date of study entry 12. Patients with preexisting nausea or vomiting in the 24 hours before receiving cisplatin chemotherapy, e.g. anticipatory emesis 13. Patients who are pregnant or breast feeding 14. Patients with a history of alcohol abuse 15. Patients with preexisting, clinically significant cardiac arrhythmia 16. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study 17. Patients who have participated in another study within the previous 28 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>